News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
205 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (21900)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3356)
June (2725)
July (2286)
August (2090)
Day
1 (117)
2 (174)
3 (44)
5 (18)
6 (63)
7 (148)
8 (162)
9 (80)
10 (92)
12 (11)
13 (86)
14 (145)
15 (167)
16 (131)
17 (117)
19 (12)
20 (202)
21 (171)
22 (152)
23 (182)
24 (89)
26 (24)
27 (111)
28 (193)
29 (219)
30 (205)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
Day
1
2
3
5
6
7
8
9
10
12
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of 2026 based on Phase 1/2 data showing a 75% slowing of disease—the same data the FDA has deemed unacceptable for a biologics license application.
April 30, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment
April 30, 2026
·
4 min read
Press Releases
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
April 30, 2026
·
5 min read
Press Releases
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
April 30, 2026
·
4 min read
Press Releases
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
April 30, 2026
·
2 min read
Press Releases
Precision Neuroscience™ Partners With UChicago Medicine Researchers to Advance Brain–Computer Interface Research
April 30, 2026
·
2 min read
Press Releases
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
April 30, 2026
·
6 min read
Press Releases
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
April 30, 2026
·
8 min read
Press Releases
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
April 30, 2026
·
2 min read
Press Releases
LEO Pharma Bolsters Rare Skin Disease Focus Through Acquisition of Replay Gene Therapy Platform
April 30, 2026
·
4 min read
Previous
14 of 21
Next
